Alzamend Neuro (ALZN) Projected to Post Quarterly Earnings on Monday

Alzamend Neuro (NASDAQ:ALZN) is projected to announce its earnings results before the market opens on Monday, March 24th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter.

Alzamend Neuro (NASDAQ:ALZN) last issued its quarterly earnings data on Monday, March 10th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.10. On average, analysts expect Alzamend Neuro to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Alzamend Neuro Stock Up 3.2 %

Shares of ALZN stock opened at $1.01 on Friday. The stock’s 50-day moving average price is $1.00 and its 200-day moving average price is $1.32. Alzamend Neuro has a 12-month low of $0.64 and a 12-month high of $15.06.

Wall Street Analysts Forecast Growth

Separately, Ascendiant Capital Markets lowered their target price on Alzamend Neuro from $32.00 to $20.00 and set a “buy” rating for the company in a research report on Monday, March 17th.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.